Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

Biotechnology

Healthcare
$75.95 +0.46%

+$0.29 today

Market cap
$3.74B
Beta
0.51
P/E (TTM)
-55.9
EPS (TTM)
-$1.12
52W Low $38.51High $85.25

Volume 0.45M

Average 0.61M

TARS Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Tarsus Pharmaceuticals, Inc.NASDAQ: TARS

Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026

Cash & equivalents rises 21.1% from a year ago

Cash & equivalents stood at $136.53M at the end of Q3 FY2026, up 21.1% from a year earlier and down 33.3% from the prior quarter. Over 3 fiscal years it compounded at +36.8% a year.

Context

  • Cash & equivalents amounted to 27.0% of total assets at the end of Q3 FY2026, up 5.9 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +21.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$136.53M-33.3% QoQ
Last fiscal yearDec 2025
$183.64M+93.7% YoY
Year agoSep 2025
$112.72M+21.1% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.1%——
1 year+93.7%——
3-year CAGR+36.8%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
183.64M USD
Year-over-year change
+93.7%
4-year CAGR
+1.7%

Cash & Equivalents vs competitors

How TARS compares with its peers on the latest reported figures

  • TARS's Sep 2026 cash & equivalents of $136.53M is the highest of the 6 companies compared; the peer median is $20.6M.
  • Its year-over-year change of +21.1% is the 2nd highest of 5, against a peer median of -35.2%.
  • Cash & equivalents amounts to 27.0% of total assets for TARS, versus a peer median of 22.6%.
TARS Competitors Peer median
Cash & Equivalents for TARS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TARSTarsus Pharmaceuticals, Inc.Sep 2026$136.53M +21.1%+36.8%27.0%
HROWHarrow Health, Inc.Mar 2026$94.64M +41.8%-8.8%22.6%
ARQTArcutis Biotherapeutics, Inc.Jun 2026$34.12M -53.3%-7.2%7.0%
VRCAVerrica Pharmaceuticals Inc.Mar 2026$20.6M -30.4%-4.2%53.1%
TTRXTurn Therapeutics Inc.Mar 2026$11.22M ——60.2%
SLGLSol-Gel Technologies Ltd.Mar 2026$10.14M -40.0%-3.9%17.3%
Peer median (excluding TARS) $20.6M-35.2%-5.7%22.6%

Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents171.33M71.66M224.95M94.82M183.64M
Short-term Investments483K145.37M2.5M196.56M233.63M
Net Receivables92K3.58M17.71M48.06M87.11M
Inventory003.11M2.62M4.37M
Other Current Assets0000560K
Total Current Assets175.95M225.38M256.13M356.71M522.78M
Property, Plant & Equipment (Net)1.83M1.53M3.35M2.87M21.75M
Goodwill00000
Intangible Assets003.87M8.33M7.37M
Long-term Investments663K371K631K3M3.87M
Tax Assets00000
Other Non-current Assets463K585K1.51M6.09M6.4M
Total Non-current Assets2.96M2.49M9.36M20.29M39.38M
Total Assets178.91M227.86M265.49M376.99M562.16M
Account Payables2.86M5.5M17.77M27.74M16.39M
Short-term Debt00000
Tax Payables55K14K000
Deferred Revenue00000
Other Current Liabilities56K000117.5M
Total Current Liabilities11.48M15.43M36.94M80.61M135.7M
Long-term Debt019.43M29.82M71.85M83.04M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities114K48K1.75M0(10.6M)
Total Non-current Liabilities699K19.53M31.57M71.85M83.04M
Total Liabilities12.18M34.96M68.5M152.46M218.73M
Common Stock4K5K5K6K6K
Retained Earnings(46.67M)(108.76M)(244.66M)(360.21M)(426.63M)
Accumulated OCI0(74K)(2K)179K381K
Other Stockholders Equity00000
Minority Interest00000
Total Equity166.73M192.9M196.99M224.53M343.43M
Total Debt1.89M20.21M30.22M72.45M93.64M
Net Debt(169.44M)(51.45M)(194.73M)(22.37M)(90.01M)

Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

Intrinsic Alpha fair value

Locked

Current Price

$75.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.